Drug Trial Radar · NCT06738745
Study of HRS-2189 Combined HRS-5041 in Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
90
Planned (sponsor's estimate)
Start
Dec 31, 2024
Primary completion
Jan 31, 2027
Study completion Aug 31, 2027
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Dec 18, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Our study is aimed to evaluate the efficacy and safety of HRS-2189 combined with HRS-5041 in metastatic prostate cancer.
Conditions
- Prostate Cancer Metastatic Disease
Interventions
HRS-2189Drug
HRS-2189
HRS-5041Drug
HRS-5041
Primary outcomes
What the sponsor says the trial is designed to measure.
- PSA50Time frame: up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan Cancer Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.